About

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. Matula, KA; Minar, P; Daraiseh, NM; Lin, L; Recker, M; Lipstein, EA. Health Expectations. 2022.

Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Whaley, KG; Xiong, Y; Karns, R; Hyams, JS; Kugathasan, S; Boyle, BM; Walters, TD; Kelsen, J; LeLeiko, N; Shapiro, J; et al. Clinical Gastroenterology and Hepatology. 2022.

Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis. Clarkston, K; Karns, R; Jegga, AG; Sharma, M; Fox, S; Ojo, BA; Minar, P; Walters, TD; Griffiths, AM; Mack, DR; et al. Journal of Crohn's and Colitis. 2022.

iBDecide: A web-based tool to promote engagement in shared decision-making among adolescents with ulcerative colitis. Daraiseh, NM; Black, A; Minar, P; Meisman, A; Saxe, M; Lipstein, EA. Patient Education and Counseling. 2022; 105:1628-1633.

Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn's Disease. Miller, TL; Schuchard, J; Carle, AC; Forrest, CB; Kappelman, MD; Adler, J; Ammoury, RF; Bass, D; Bass, J; Benkov, K; et al. Journal of Pediatrics. 2022; 242:86-92.e3.

Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Colman, RJ; Xiong, Y; Mizuno, T; Hyams, JS; Noe, JD; Boyle, B; D’Haens, GR; van Limbergen, J; Chun, K; Yang, J; et al. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.

Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Colman, RJ; Tsai, YT; Jackson, K; Boyle, BM; Noe, JD; Hyams, JS; D'Haens, GR A M; Van Limbergen, J; Rosen, MJ; Denson, LA; et al. Inflammatory Bowel Diseases. 2021; 27:1045-1051.

Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Xiong, Y; Mizuno, T; Colman, R; Hyams, J; Noe, JD; Boyle, B; Tsai, YT; Dong, M; Jackson, K; Punt, N; et al. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Hellmann, J; Etter, RK; Denson, LA; Minar, P; Hill, D; Dykes, DM; Rosen, MJ. Pediatric Quality and Safety. 2021; 6.

Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Colman, RJ; Portocarrero-Castillo, A; Chona, D; Hellmann, J; Minar, P; Rosen, MJ. Inflammatory Bowel Diseases. 2021; 27:507-515.

From the Blog


Perspective on Alternative IBD Diets
BlogRare and Complex Conditions

Perspective on Alternative IBD Diets

By Phillip Minar, MD11/4/2016

IBD: Tips for Managing Steroid Side Effects
BlogRare and Complex Conditions

IBD: Tips for Managing Steroid Side Effects

By Phillip Minar, MD7/8/2016

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey